Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir

The oral prodrug fostemsavir (GSK3684394, formerly BMS‐663068) is an antiretroviral treatment for HIV‐1. Fostemsavir is metabolized to its active moiety, temsavir, a first‐in‐class HIV‐1 attachment inhibitor that binds to the viral envelope glycoprotein 120. Long‐term antiretroviral therapy, the res...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical pharmacology 2021-07, Vol.61 (7), p.939-953
Hauptverfasser:	Magee, Mindy, Slater, Jill, Mannino, Frank, Ackerman, Peter, Llamoso, Cyril, Moore, Katy
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Adverse events Age Factors Aged Anti-HIV Agents - pharmacokinetics Anti-HIV Agents - therapeutic use Antiretroviral therapy Body Mass Index Creatinine - blood Female fostemsavir Glomerular Filtration Rate Hemodialysis hepatic impairment Hepatic Insufficiency - epidemiology Hepatic Insufficiency - metabolism HIV HIV Infections - drug therapy HIV‐1 Human immunodeficiency virus Humans Kidney diseases Life Sciences & Biomedicine Life span Liver diseases Liver Function Tests Male Middle Aged Organophosphates - pharmacokinetics Organophosphates - therapeutic use Patient Acuity Pharmacokinetics Pharmacology & Pharmacy Piperazines - pharmacokinetics Piperazines - therapeutic use Prodrugs Racial Groups renal impairment Renal Insufficiency - epidemiology Renal Insufficiency - metabolism Science & Technology Sex Factors temsavir
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!